The companies have also initiated a phase 1/2/3 study to evaluate different doses and dosing regimens of the BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age.
Pfizer and BioNTech are requesting emergency use authorization (EUA) of a 10-µg booster dose of the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age.
The request in this age group is supported by safety and immunogenicity data from the companies’ bivalent omicron BA.1-adapted vaccine, nonclinical and manufacturing data from the companies’ 10-µg bivalent omicron BA.4/BA.5-adapted vaccine, and preclinical data from the companies’ omicron BA.4/BA.5-adapted vaccine.
An application to extend the omicron BA.4/BA.5-adapted bivalent vaccine marketing authorization to include children ages 5 through 11 years will be submitted to the European Medicines Agency (EMA) in the coming days.
The companies have also initiated a phase 1/2/3 study to evaluate the safety, tolerability, and immunogenicity of different doses and dosing regimens of the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age. The study will have four substudies examining different dosing regimens and ages. This includes:
Related: FDA Authorizes Pfizer, Moderna Updated COVID-19 Boosters
In August 2022, the FDA amended the emergency use authorizations of both the updated Moderna and the Pfizer/BioNTech COVID-19 booster vaccines that include the omicron variants. The updated boosters are bivalent vaccines and contain two messenger RNA (mRNA) components, one of the original strain of the SARS-CoV-2 and the BA.1, BA.4 and BA.5 omicron variant.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More